Bill would change FDA rules for new drug and treatment testing.
H.R. 10857 — To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes. · Filed by Jake Auchincloss (D-MA) · 1 cosponsor · Introduced Oct 22, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill would amend two federal laws about drugs and health. It aims to speed up how new treatments are developed and tested. The full text is not yet available.
Who it affects
Drug companies, patients, and the FDA would be affected. New medicines could become available faster.
One thing to notice
The bill title does not say what specific changes it makes.
From the analysis of the bill text, linked under Primary records below.
Where it stands
1 cosponsor: 1 Republicans.
- Oct 22, 2026 — Introduced · Congress.gov: “Introduced in House”
- Oct 22, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Oct 26, 2026; transparency and hidden-provision scores are compared against the median of 16,595 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-28.
“Bill would change FDA rules for new drug and treatment testing.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr10857/simple Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.